Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Sep;8(9):1509-28.
doi: 10.2217/nnm.13.118.

Current trends in the use of liposomes for tumor targeting

Affiliations
Review

Current trends in the use of liposomes for tumor targeting

Pranali P Deshpande et al. Nanomedicine (Lond). 2013 Sep.

Abstract

The use of liposomes for drug delivery began early in the history of pharmaceutical nanocarriers. These nanosized, lipid bilayered vesicles have become popular as drug delivery systems owing to their efficiency, biocompatibility, nonimmunogenicity, enhanced solubility of chemotherapeutic agents and their ability to encapsulate a wide array of drugs. Passive and ligand-mediated active targeting promote tumor specificity with diminished adverse off-target effects. The current field of liposomes focuses on both clinical and diagnostic applications. Recent efforts have concentrated on the development of multifunctional liposomes that target cells and cellular organelles with a single delivery system. This review discusses the recent advances in liposome research in tumor targeting.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Hydrophilic and hydrophobic drugs encapsulated within a PEGylated liposome.
Figure 2
Figure 2
Passive targeting via the enhanced permeability and retention effect.
Figure 3
Figure 3
Surface receptor-mediated endocytosis.
Figure 4
Figure 4. Stimuli-sensitive multifunctional liposomes with low pH-degradable bonds in the tumor microenvironment
CPP: Cell-penetrating peptide.
Figure 5
Figure 5
A multifunctional liposome for targeted drug delivery.

Similar articles

Cited by

References

    1. Voinea M, Simionescu M. Designing of `intelligent' liposomes for efficient delivery of drugs. J. Cell. Mol. Med. 2002;6(4):465–474. - PMC - PubMed
    1. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer. 2008;8(6):473–480. - PubMed
    1. Huwyler J, Drewe J, Krähenbühl S. Tumor targeting using liposomal antineoplastic drugs. Int. J. Nanomed. 2008;3(1):21–29. - PMC - PubMed
    1. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug. Discov. 2005;4(2):145–160. - PubMed
    1. Elbayoumi T, Torchilin V. Current trends in liposome research. In: Weissig V, editor. Liposomes. Humana Press; NJ, USA: 2010. pp. 1–27. - PubMed
    2. ■■ Provides a brief overview of various liposomal products currently under development at the experimental and preclinical level.

Publication types

MeSH terms